多烯紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究  

A Clinical Study on Paclitaxel Chemotherapy Combined with Cisplatin for Advanced Non-small Cell Lung Cancer

作　　者：刘楠[1] 任爱芳[1] 孙青刚[1] 刘霖[1] 邹维华[1] 宋晓菲[1] 

机构地区：[1]解放军第401医院血液肿瘤科,山东青岛266071

出　　处：《中华临床医学杂志》2007年第9期12-14,共3页Chinese Journal of Clinical Practical Medicine

摘　　要：目的观察紫杉醇联合顺铂化疗方案治疗非小细胞肺癌的近期疗效与毒副作用。方法多烯紫杉醇75mg／m^2静脉点滴d1，顺铂80mg／m^2分3d静脉点滴d1～d3；每21天为1周期，至少治疗2个周期。结果全组共21例，完全缓解（CR）2例，部分缓解（PR）16例，总有效率85，7％。中位生存期17，6个月，1、2年生存率分别为57．6％、36．4％。主要毒副反应包括轻度骨髓抑制、脱发和关节肌肉疼痛，但均可耐受。结论多烯紫杉醇联合顺铂化疗方案是治疗晚期非小细胞肺癌的有效方法，能显著缓解症状，改善生活质量，延长生存期。Objective To evaluate the efficacy and toxicity of chemotherapy of paclitaxel combined with cisplatin for advanced non-small cell lung cancer（NSCLC）. Methods From August 2003 to July 2005,21 patients with advanced non-small cell lung cancer were enrolled in this strdy. Those patients received paclitaxel 75mg/m^2 intravenously onday l and cisplatin 80mg/m^2 intravenously on day 1-3.The chemotherapy was repeated every 21 days, and at least two cycles, Results Among the 21 patients, two got complete response（CR）, 16 partial response（PR）2 had stable disease and 1 progressive disease, with an overall response rate of （18/21）. The median survival duration was 17.6 months. The 1- and 2- year survival rates were 57.6% and 36.4%, respectively. The main toxicities were mild myelosuppression, alopecia, and arthralgia/bone pain. Its side effects are mild and manageable. Conclusion The chemotherapy of Paclitaxel combined with cisplatin is effective for advanced non-small cell lung cancer and can ameliorate the symptom,and improve the survival rate and life quality of those patients.

关 键 词：非小细胞肺癌 紫杉醇 顺铂 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]